QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)

McKesson (MCK) Competitors

$519.31
+3.07 (+0.59%)
(As of 02/26/2024 ET)

MCK vs. COR, CAH, BDX, EW, HCA, ZTS, TAK, GSK, IDXX, and DXCM

Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), HCA Healthcare (HCA), Zoetis (ZTS), Takeda Pharmaceutical (TAK), GSK (GSK), IDEXX Laboratories (IDXX), and DexCom (DXCM). These companies are all part of the "medical" sector.

McKesson vs.

McKesson (NYSE:MCK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

McKesson received 205 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 73.95% of users gave McKesson an outperform vote while only 65.00% of users gave Cencora an outperform vote.

CompanyUnderperformOutperform
McKessonOutperform Votes
931
73.95%
Underperform Votes
328
26.05%
CencoraOutperform Votes
726
65.00%
Underperform Votes
391
35.00%

McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.5%. Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays out 11.2% of its earnings in the form of a dividend. Cencora pays out 22.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

McKesson has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

McKesson currently has a consensus price target of $517.86, suggesting a potential downside of 0.67%. Cencora has a consensus price target of $214.90, suggesting a potential downside of 9.89%. Given McKesson's stronger consensus rating and higher possible upside, equities research analysts plainly believe McKesson is more favorable than Cencora.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
McKesson
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82
Cencora
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63

McKesson has a net margin of 0.99% compared to Cencora's net margin of 0.69%. Cencora's return on equity of 323.23% beat McKesson's return on equity.

Company Net Margins Return on Equity Return on Assets
McKesson0.99% -262.63% 5.96%
Cencora 0.69%323.23%4.13%

82.7% of McKesson shares are owned by institutional investors. Comparatively, 93.1% of Cencora shares are owned by institutional investors. 0.2% of McKesson shares are owned by insiders. Comparatively, 15.8% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$276.71B0.25$3.56B$22.0723.66
Cencora$262.17B0.18$1.75B$9.1825.99

In the previous week, McKesson had 6 more articles in the media than Cencora. MarketBeat recorded 18 mentions for McKesson and 12 mentions for Cencora. McKesson's average media sentiment score of 0.72 beat Cencora's score of 0.13 indicating that McKesson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
McKesson
8 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Cencora
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

McKesson beats Cencora on 14 of the 20 factors compared between the two stocks.


Get McKesson News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCK vs. The Competition

MetricMcKessonDrugs, proprietaries, & sundries IndustryMedical SectorNYSE Exchange
Market Cap$68.62B$17.25B$4.83B$17.15B
Dividend Yield0.48%1.23%5.40%3.56%
P/E Ratio23.6615.89166.2421.00
Price / Sales0.252.523,007.607.35
Price / Cash16.0210.8724.9816.83
Price / Book-47.5214.154.515.74
Net Income$3.56B$721.61M$108.22M$855.91M
7 Day Performance2.18%9.29%112.15%0.79%
1 Month Performance7.66%5.14%120.89%2.54%
1 Year Performance45.41%27.09%133.64%6.17%

McKesson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COR
Cencora
3.8743 of 5 stars
$232.37
+0.3%
$209.78
-9.7%
+49.6%$46.35B$262.17B25.3146,000Analyst Report
CAH
Cardinal Health
4.9308 of 5 stars
$105.37
+0.9%
$101.38
-3.8%
+39.3%$25.63B$205.01B41.4848,000Analyst Report
BDX
Becton, Dickinson and Company
4.7653 of 5 stars
$240.69
0.0%
$279.17
+16.0%
+3.5%$69.56B$19.49B57.0473,000
EW
Edwards Lifesciences
4.6095 of 5 stars
$86.92
+1.0%
$87.38
+0.5%
+15.1%$52.24B$6.00B37.7919,800Insider Selling
HCA
HCA Healthcare
4.7685 of 5 stars
$308.62
+0.0%
$304.26
-1.4%
+26.6%$82.61B$64.97B16.26294,000
ZTS
Zoetis
4.7837 of 5 stars
$186.66
-0.9%
$223.78
+19.9%
+18.6%$85.47B$8.54B36.8214,100
TAK
Takeda Pharmaceutical
3.8538 of 5 stars
$14.82
+1.4%
$21.33
+43.9%
-4.9%$46.90B$29.81B22.4549,095
GSK
GSK
2.8167 of 5 stars
$42.03
+0.2%
N/A+22.1%$86.51B$37.71B13.9669,400Analyst Revision
IDXX
IDEXX Laboratories
4.373 of 5 stars
$551.21
-0.8%
$591.50
+7.3%
+23.1%$46.17B$3.66B54.7410,780Positive News
DXCM
DexCom
4.6364 of 5 stars
$117.87
+0.7%
$134.64
+14.2%
+5.6%$45.12B$3.62B89.989,600

Related Companies and Tools

This page (NYSE:MCK) was last updated on 2/26/2024 by MarketBeat.com Staff